Tekin A, Ozen H
Hacettepe University, Department of Urology, Ankara, Turkey.
Int Urol Nephrol. 2000;32(1):59-62. doi: 10.1023/a:1007152016341.
Of 50 patients with pT3b, pT4 and/or pN+ disease after cystectomy, 27 were administered adjuvant four cycles of cisplatin, methotrexate and vinblastine (CMV) and 23 were followed expectantly (no-treatment group). Median follow-up was 14 months in CMV group and 11 months in no-treatment group. Median recurrence-free survival was 21 months in CMV group and 17 months in no-treatment group (p = 0.573). Median overall survival was 41+ months in CMV group and 84+ months in no-treatment group, respectively (p = 0.501). In our experience, adjuvant chemotherapy after cystectomy seemed not to provide a survival advantage.
在50例膀胱切除术后患有pT3b、pT4和/或pN+疾病的患者中，27例接受了顺铂、甲氨蝶呤和长春碱（CMV）辅助化疗4个周期，23例进行观察等待（未治疗组）。CMV组的中位随访时间为14个月，未治疗组为11个月。CMV组的中位无复发生存期为21个月，未治疗组为17个月（p = 0.573）。CMV组的中位总生存期分别为41 +个月，未治疗组为84 +个月（p = 0.501）。根据我们的经验，膀胱切除术后辅助化疗似乎并未提供生存优势。
